Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NGM
DateTimeSourceHeadlineSymbolCompany
05/04/202413:19GlobeNewswire Inc.NGM Bio Announces Closing of Tender OfferNASDAQ:NGMNGM Biopharmaceuticals Inc
19/03/202421:30GlobeNewswire Inc.NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202420:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202420:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202420:05GlobeNewswire Inc.NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NGMNGM Biopharmaceuticals Inc
08/03/202422:32Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:NGMNGM Biopharmaceuticals Inc
08/03/202422:21Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:NGMNGM Biopharmaceuticals Inc
26/02/202422:11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:NGMNGM Biopharmaceuticals Inc
26/02/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
26/02/202414:03GlobeNewswire Inc.NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPNASDAQ:NGMNGM Biopharmaceuticals Inc
20/02/202421:01GlobeNewswire Inc.NGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
14/02/202423:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
22/01/202411:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
18/01/202423:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
18/01/202423:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
18/01/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
17/01/202421:47GlobeNewswire Inc.NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
09/01/202413:00GlobeNewswire Inc.NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet NeedNASDAQ:NGMNGM Biopharmaceuticals Inc
02/01/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
04/12/202322:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
04/12/202321:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
13/11/202314:45GlobeNewswire Inc.NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver MeetingĀ®NASDAQ:NGMNGM Biopharmaceuticals Inc
08/11/202323:13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
08/11/202323:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
08/11/202323:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
08/11/202323:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
07/11/202321:05GlobeNewswire Inc.NGM Bio to Participate in Upcoming Investor ConferencesNASDAQ:NGMNGM Biopharmaceuticals Inc
02/11/202320:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NGMNGM Biopharmaceuticals Inc
02/11/202320:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
02/11/202320:01GlobeNewswire Inc.NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:NGMNGM Biopharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NGM

Your Recent History

Delayed Upgrade Clock